

Special Issue

In Memory of Stephen Oroszlan

Message from the Guest Editor

Stephen Oroszlan was a pioneer in the analysis of retroviral proteins. His groundbreaking contributions to the field paved the way for the development of inhibitors of retroviral proteases, now among the most potent weapons in our arsenal of anti-HIV-1 therapies. Sadly, Steve passed away in May 2020. *Viruses* is planning a Special Issue in honor of his work and scientific legacy. We invite submissions on subjects related to Steve's work, such as proteolysis in viral maturation, post-translational modifications of viral proteins, recoding mechanisms used by viruses, etc., particularly those reporting recent progress in these fields. Original research reports, reviews, and brief commentaries on Steve's influence on the field would all be welcome. Dr. Alan R. Rein

Guest Editor

Dr. Alan Rein

HIV Dynamics and Replication Program, National Cancer Institute-Frederick, National Institutes of Health, USA

Deadline for manuscript submissions

closed (30 April 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/50471

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).